According to CoinMeta, the National Health Commission, the National Healthcare Security Administration, the National Administration of Traditional Chinese Medicine, and the National Disease Control and Prevention Administration issued a notice today (the 10th) titled "On Further Improving the Safe and Rational Allocation and Use of Innovative Drugs." The notice puts forward specific policy measures focusing on key aspects of the safe and rational allocation and use of innovative drugs, including promoting rational allocation, strengthening training and guidance, optimizing usage conditions, and improving management practices. It proposes to implement relevant medical service price items for pharmaceutical services, further improve support and guarantee measures, and optimize the policy environment for the use of innovative drugs. It also emphasizes that there should be no restrictions on the total number of drug varieties and specifications in medical institutions, and it is clarified that innovative drugs are not included in performance monitoring indicators such as the average cost of drugs per outpatient visit or per inpatient visit in public medical institutions.